UK Markets close in 5 hrs 34 mins

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
5.08-0.17 (-3.24%)
As of 11:40AM CET. Market open.
Full screen
Previous close5.25
Open5.25
Bid5.03 x 0
Ask5.07 x 0
Day's range4.91 - 5.25
52-week range3.17 - 9.76
Volume333,050
Avg. volume400,628
Market cap844.128M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments

    Press Release Stockholm, Sweden, November 30, 2021 Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, and PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation, announced to

  • Globe Newswire

    Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells

    Press ReleaseStockholm, Sweden, November 22, 2021Immunicum Publishes DCP-001 Mechanism of Action in the Journal CellsImmunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today the publication of a scientific journal article describing the mechanism of action for its cell-based cancer relapse vaccine DCP-001. The publication in the peer-reviewed journal Cells details the interaction between DCP-001

  • Globe Newswire

    Immunicum to Present New Research Data at The Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Press ReleaseStockholm, Sweden, November 9, 2021Immunicum to Present New Research Data at The Society for Immunotherapy of Cancer (SITC) Annual MeetingImmunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today that it will present new data on its cancer relapse vaccine DCP-001 at the The Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021), being held Wednesday, November 10, 2021 to